AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 72 min read$CLBT

Hogan Thomas E. sold $1.6M of CLBT

Hogan Thomas E. (Chief Executive Officer) sold 103,188 shares of Cellebrite DI Ltd. (CLBT) at $15.76 ($1.63M total) on 2026-07-02.

Original reporting
SEC EDGAR · Hogan Thomas E.
Published Jul 7, 2026, 11:29 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 7, 2026, 11:33 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$CLBT
Neutral
high confidence
Mentioned
$CLBT
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLBTNeutralLow
01

Why it matters

Traders may monitor for follow-on insider activity, but the text contains no new guidance, contracts, litigation, or operational developments.

02

Market read

A $1.63M CEO open-market sale is disclosed; likely sentiment-only unless corroborated by other new catalysts.

03

What to watch

No 10b5-1 plan is stated, but the article also provides no reason for the sale or any concurrent buying/selling pattern beyond this single transaction.

Relevance 6/10Novelty 5/10Timing: Filed July 7; reflects sale executed July 2.

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Cellebrite DI Ltd. (CLBT).

Company-level read

Ticker impact

$CLBTNeutralHigh confidence
Context

Cellebrite CEO Hogan Thomas E. sold 103,188 shares in an open-market transaction worth about $1.63M, per Form 4 filed July 7.

Expected impact

Low near-term impact; any reaction is likely limited unless accompanied by other company-specific news.

Evidence & confidence

The filing is a Form 4 insider sale with no 10b5-1 plan and no accompanying operational/regulatory update in the text.

Market effects

Sector

Minimal—this is an issuer-specific insider transaction with no sector-wide signal provided.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale could be for diversification or liquidity needs; without additional context, it may not indicate deteriorating fundamentals.

Key entities

  • issuer
    Cellebrite DI Ltd.

    Public company subject of the Form 4 insider sale disclosure.

  • insider
    Hogan Thomas E.

    CEO and officer/director who sold shares via open-market sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CLBT insider trading history →

Related articles

AUG 20
$CLBTMedAI 8/10

Cellebrite (CLBT) Q2 2026 Earnings Call Transcript

Cellebrite (CLBT) announced Shiv Ramji as its new CEO, replacing Tom Hogan. The company missed Q2 revenue expectations due to delayed large transactions and lower-than-expected ARR uplift. Despite this, they raised their full-year adjusted EBITDA target. Ramji outlined plans to improve sales execution and forecasting discipline. The company sees growth in new products and federal business, with a 25% increase in Defense and Intelligence ARR.

yahoo.com3 min
AUG 16
$CLBTMedAI 8/10

Why Cellebrite DI (CLBT) Is Down 30.4% After Cutting 2026 Outlook And Announcing CEO Transition

Cellebrite DI Ltd. reported half-year 2026 results and cut its full-year revenue outlook to US$555 million to US$561 million, implying 17% to 18% growth. The company also announced a CEO transition, with Shiven Ramji succeeding Thomas E. Hogan. The guidance reduction, weaker profitability, and delayed large government contracts contributed to a sharp stock drop.

simplywall.st6 min
AUG 15
$CLBTMedAI 8/10

Cellebrite DI Ltd. Q2 2026 Earnings Call Summary

Cellebrite DI Ltd. reported Q2 2026 results below expectations, citing delayed large transactions and procurement hurdles tied to foreign entity status. Full-year ARR guidance was cut to $550m–$560m, while adjusted EBITDA was raised to $153m–$159m. Management said Insights installed base reached 65% and Genesis launched with $400k ARR.

yahoo.com6 min